Transcription
The longer transcript encoded by NM_003927.3, mRNA length of 2584 bp, is expressed ubiquitiously (according to symatlas).
The shorter transcript NM_015832.3, mRNA length of 1357 bp is expressed in germ cells (according to symatlas).
Protein

Description
In somatic tissues MBD2 is expressed from a single transcript, and is detected by western blot as 2 stable proteins at approximately 50 kDa (MBD2a) and 30 kDa (MBD2b). Human MBD2a (Q9UBB5) has 411 amino acids. It is unknown whether MBD2b is due to use of an alternative translation start site (creating protein of 262 amino acids) or due to protein cleavage/processing/degradation. Human germ cells express a short form of MBD2 from the alternative transcript with an expected length of 302 amino acids.
Expression
MBD2a and MBD2b are expressed in all tissues tested with highest levels in spleen and colon nuclei (nonpublished observation).
Localisation
MBD2 is a nuclear protein. MBD2-GFP localises to major satellite in mouse ES cells, but not in DNA methylation deficient cells (Hendrich and Bird, 1998) .
MBD2 is expressed as 2 transcripts. NM_003927.3 coding sequence in blue and NM_015832.3 in red. Boxes represent exons and arrows represent transcriptional start sites.
MBD2 (methyl CpG binding domain protein 2)
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MBD: methyl binding domain, P: phosphorylation detected.
Function
MBD2 is a methyl binding protein that is thought to repress gene expression as part of the NuRD complex. The NuRD complex was identified independently by four separate groups (Wade et al., 1998; Tong et al., 1998; Xue et al., 1998; Zhang et al., 1998) . NuRD consists of a chromatin remodelling ATPase Mi2alpha or beta, histone deacetylase HDAC1/HDAC2, MTA1 or MTA2, RbAp46/RbAp48, p66alpha/beta and can also contain MBD2 or MBD3. TAP tagged MBD2a associates with NuRD with equimolar stoichometry implying that most MBD2a is complexed with NuRD in cells (Le Guezennec et al., 2006) . MBD2 is required for repression of methylated reporter genes (Hendrich, 2001) and many endogenous target genes of MBD2 have been reported. However the global genomic targets of MBD2 have not been characterised. MBD2 knock out are viable and fertile, and show only mild physiological defects. These are abnormal maternal behaviour and T helper cell deficiencies (Hendrich, 2001; Hutchins, 2002; Hutchins, 2005) .
Homology
MBD2 is a member of the methyl-binding domain proteins (Hendrich and Bird, 1998) . Other members of this family are MeCp2, MBD2, MBD3 and MBD4 (Klose and Bird, 2006) . These proteins share a region of homology (145-213 of MBD2a), which have been shown to form a stable domain consisting of a beta sheet, an alpha helix and a positioned loop (Ohki et al., 2001) . The crystal structure of the MBD of MeCP2 complexed with a methylated CpG containing 20mer of DNA indicates that the protein-DNA interactions are dependent on water molecules (Ho et al., 2008) . The protein with closest homology to MBD2 is MBD3, however MBD3 has two crucial amino acid substitutions in the MBD and does not specifically bind to methylated DNA (Hendrich and Tweedie, 2003) .
Mutations
Note MBD2 is mutated only infrequently in human cancer tissues.
Implicated in
Intestinal tumorigenesis
Note
MBD2
-/-APC min/+ mice have fewer intestinal tumors and survive longer than MBD2 +/+ APC min / + mice (Sansom, 2003) . These results imply MBD2 is required for tumorigenesis. Although the mechanism is unknown, possibilities are listed below: 1) MBD2 may repress tumor supressor genes (therefore in the absence of MBD2, tumor repressor expression would be upregulated). In cancer cell lines MBD2 has been found to bind to methylated regions of tumor supressor genes GSTP1, p14 and p16 (Stirzaker, 2004; Le Guezennec, 2006; Martin, 2008) . 2) MBD2 may repress a repressor of WNT signalling (therefore in the absence of MBD2, WNT signalling would be reduced). One candidate for this is Lect2 (Phesse, 2008) . 3) In mice MBD2 is required for normal T cell differentiation and MBD2-/-mice have impaired immune responses. This could contribute to the MBD2 requirement in tumor formation in the APCmin/+ strain (Hutchins, 2002; Hutchins, 2005) . 4) Other mechanisms are possible, such as a role of mbd2 in higher order chromatin or silencing of heterochromatin regulating tumorigenesis. However this has not been tested. Knock down of MBD2 in human cancer cell lines reduced tumor volume when implanted into nude mice (Campbell, 2004) . MBD2 expression levels in human cancer tissues have been analysed in multiple studies with differing results. One study found MBD2 expression was low in colorectal and stomach cancers (Kanai, 1999) , whereas other studies found high expression in cancer tissues. These discrepancies are likely due to differences between control genes used as well as differences between cancer tissues.
